Major holder Dipan Patel cuts Amneal Pharmaceuticals (AMRX) stake to 5.4%

Rhea-AI Filing Summary

Dipan Patel filed Amendment No. 5 to a Schedule 13D for Amneal Pharmaceuticals, Inc., updating his beneficial ownership in the company’s Class A common stock. The filing reports beneficial ownership of 16,904,263 shares, representing 5.4% of the Class A common stock, based on 314,629,101 shares outstanding disclosed in Amneal’s Form 10-K filed on February 27, 2026.

Between November 14, 2024 and December 31, 2025, trusts controlled by Patel sold 6,924,729 Amneal Class A shares in open market transactions at prices between $7.74 and $12.42 per share. After these sales, Patel, through those trusts, retains sole voting and dispositive power over the 16.9 million shares reported.

Insights

Equity ownership and governance analyst

Large shareholder reduced but still holds a 5.4% stake.

The amendment shows Dipan Patel, through controlled trusts, sold 6,924,729 Amneal Class A shares in open market trades at prices from $7.74 to $12.42 between November 14, 2024 and December 31, 2025. These are discretionary sales rather than automatic grants or tax events.

Following the transactions, Patel reports beneficial ownership of 16,904,263 shares, or 5.4% of the class, based on 314,629,101 shares outstanding from the company’s Form 10-K filed on February 27, 2026. He retains sole voting and dispositive power over this position, indicating continued status as a significant, though not controlling, shareholder.

This kind of reduction by a large holder can reflect portfolio rebalancing or other personal considerations; the amendment itself does not provide reasons. Future ownership updates in subsequent beneficial ownership filings may clarify whether this is a one-time reduction or part of a broader change in stake.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)

Amneal Pharmaceuticals, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.01

(Title of Class of Securities)

03168L105

(CUSIP Number)

Christine Krentz
4 Gatehall Drive,
Parsippany, NJ, 07054
(908) 409-6700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

12/31/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 03168L105

1

Name of reporting person

Patel Dipan

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 16,904,263.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 16,904,263.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

16,904,263.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.4 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

The percentage of ownership of the Class A Common Stock by the Reporting Person presented in this Statement is based on 314,629,101 shares of Class A Common Stock outstanding, as disclosed in the New Issuer's Annual Report on Form 10-K, filed on February 27, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Class A Common Stock, par value $0.01
(b)	Name of Issuer: Amneal Pharmaceuticals, Inc.
(c)	Address of Issuer's Principal Executive Offices: 400 Crossing Blvd, Bridgewater, NEW JERSEY , 08807.
Item 4.	Purpose of Transaction
	This Amendment No. 5 to Schedule 13D (this "Amendment No. 5") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 5, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the New Issuer. Capitalized terms used but not defined in this Amendment No. 5 shall have the meanings set forth in the Schedule 13D. Between November 14, 2024 and December 31, 2025, trusts controlled by the Reporting Person sold 6,924,729 shares of Class A Common Stock in open market transactions at prices per share between $7.74 and $12.42.
Item 5.	Interest in Securities of the Issuer
(b)	The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by the Reporting Person, as well as the number of shares of Class A Common Stock as to which the Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 314,629,101 shares of Class A Common Stock outstanding, as disclosed in the New Issuer's Annual Report on Form 10-K, filed on February 27, 2026: Reporting Person - Dipan Patel Amount Beneficially Owned - 16,904,263 Percent of Class - 5.4 Sole power to vote or to direct the vote - 16,904,263 Shared power to vote or to direct the vote - 0 Sole power to dispose or to direct the disposition - 16,904,263 Shared power to dispose or to direct the disposition - 0 The Reporting Person may be deemed to beneficially own 16,904,263 shares of Class A Common Stock held of record by trusts controlled by the Reporting Person.
(c)	The information set forth in Item 4 of this Amendment No. 5 is incorporated by reference herein.
(d)	None.
(e)	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Patel Dipan

Signature:	Dipan Patel
Name/Title:	Patel Dipan
Date:	03/26/2026

FAQ

How many Amneal Pharmaceuticals (AMRX) shares does Dipan Patel currently beneficially own?

Dipan Patel beneficially owns 16,904,263 shares of Amneal Class A common stock. This figure reflects shares held through trusts he controls and represents a 5.4% ownership stake, based on 314,629,101 Class A shares outstanding disclosed in Amneal’s Form 10-K.

What percentage of Amneal Pharmaceuticals (AMRX) Class A common stock does Dipan Patel hold after this amendment?

After this amendment, Dipan Patel holds 5.4% of Amneal’s Class A common stock. The percentage is calculated using 314,629,101 shares outstanding, as reported in Amneal’s Form 10-K filed on February 27, 2026, and reflects his 16,904,263 beneficially owned shares.

How many Amneal (AMRX) shares did trusts controlled by Dipan Patel sell, and over what period?

Trusts controlled by Dipan Patel sold 6,924,729 Amneal Class A shares. These were open market transactions executed between November 14, 2024 and December 31, 2025, as disclosed in Amendment No. 5 to his Schedule 13D filing for Amneal Pharmaceuticals.

At what prices did Dipan Patel’s controlled trusts sell Amneal Pharmaceuticals (AMRX) shares?

The trusts controlled by Dipan Patel sold Amneal Class A common shares at prices between $7.74 and $12.42 per share. All of these were open market transactions executed from November 14, 2024 through December 31, 2025, according to the amended Schedule 13D disclosure.

Does Dipan Patel have sole voting and dispositive power over his Amneal (AMRX) shares?

Yes. The filing reports that Dipan Patel has sole voting power and sole dispositive power over 16,904,263 Amneal Class A shares. It shows zero shared voting or shared dispositive power, with the shares held of record by trusts he controls.

What document did Amneal (AMRX) use to disclose the outstanding share count referenced in this 13D amendment?

The outstanding share count comes from Amneal’s Annual Report on Form 10-K. That report, filed on February 27, 2026, disclosed 314,629,101 shares of Class A common stock outstanding, which the Schedule 13D amendment uses to calculate Dipan Patel’s 5.4% stake.